With isocitrate lyase for the target screening of anti-tuberculosis drugs Mochidome.docVIP

 PAGE \* MERGEFORMAT 23 With isocitrate lyase for the target screening of anti-tuberculosis drugs Mochidome [Abstract] into the 21st century, tuberculosis remains a clinical morbidity and mortality in the highest infectious diseases. Currently, Mycobacterium tuberculosis (Mycobacterium tuberculosis) of the multi-drug resistance, as well as the role of anti-tuberculosis drugs in the course of Mycobacterium tuberculosis to remain the holder of the state, has become the world’s major obstacles to TB control. Isocitrate lyase (isocitrate lyase, ICL) is the glyoxylate cycle pathway, one of the key rate-limiting enzyme determined that the holder of Mycobacterium tuberculosis to remain sexually. In the text, we will describe the isocitrate lyase and structural characteristics of the fundamental nature of his hope for ICL inhibitors knowledge of the region to promote the anti-Mycobacterium tuberculosis drugs who left the study. [Keywords:] Isocitrate lyase; Mycobacterium tuberculosis; who left the state ABSTRACT Getting into the 21st century, tuberculosis remains a leading cause of mortality worldwide. The main obstacles to the global control of the disease are emerging multi-drug resistant strains of Mycobacterium tuberculosis and the recalcitrance of persistent infections to treatment with conventional anti-TB drugs . Isocitrate lyase (ICL) is a key rate-limiting enzyme in the glyoxylate bypass, and it is needed for persistent Mycobacterium tuberculosis to get energy. Consequently, isocitrate lyase is an attractive targets for the development of new antituberculosis agents. In this paper, the characteristion and structure of ICL were decribed. Our understanding of the inhibitor-bound sites will provide a springboard to find drugs which target the tuberculosis infection. KEY WORDS Isocitrate lyase; Mycobacterium tuberculosis; Persistent infections Mycobacterium tuberculosis to remain the holder of the bottleneck state is one of the treatment of tuberculosis. Who